eIF-4E expression and its role in malignancies and metastases

被引:615
作者
De Benedetti, A
Graff, JR
机构
[1] Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA
[2] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Div, Indianapolis, IN 46285 USA
关键词
eIF-4E oncogene; tumor vascularization; tumor progression; protein translation; tumor marker; metastasis;
D O I
10.1038/sj.onc.1207545
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The contribution of the mRNA cap-binding protein, eIF-4E, to malignant transformation and progression has been illuminated over the past decade. eIF-4E overexpression has been demonstrated in human tumors of the breast, head and neck, colon, prostate, bladder, cervix and lung, and has been related to disease progression. Overexpression of eIF-4E in experimental models dramatically alters cellular morphology, enhances proliferation and induces cellular transformation, tumorigenesis and metastasis. Conversely, blocking eIF-4E function by expression of antisense RNA, or overexpression of the inhibitory eIF-4E binding proteins (4E-BPs), suppresses cellular transformation, tumor growth, tumor invasiveness and metastasis. Although eIF-4E regulates the recruitment of mRNA to ribosomes, and thereby globally regulates cap-dependent protein synthesis, eIF-4E contributes to malignancy by selectively enabling the translation of a limited pool of mRNAs - those that generally encode key proteins involved in cellular growth, angiogenesis, survival and malignancy (e.g. cyclin D1, c-myc, vascular endothelial growth factor, matrix metalloprotease 9). A deeper understanding of the role of eIF-4E in regulating the translation of the diverse gene products involved in all aspects of malignancy will improve the capacity to exploit eIF-4E as a therapeutic target and as a marker for human cancer progression.
引用
收藏
页码:3189 / 3199
页数:11
相关论文
共 139 条
  • [11] BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633
  • [12] Role of two upstream open reading frames in the translational control of oncogene mdm2
    Brown, CY
    Mize, GJ
    Pineda, M
    George, DL
    Morris, DR
    [J]. ONCOGENE, 1999, 18 (41) : 5631 - 5637
  • [13] Calkhoven CF, 2000, GENE DEV, V14, P1920
  • [14] Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
    Capoulade, C
    Bressac-de Paillerets, B
    Lefrère, I
    Ronsin, M
    Feunteun, J
    Tursz, T
    Wiels, J
    [J]. ONCOGENE, 1998, 16 (12) : 1603 - 1610
  • [15] Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E:: evidence for internal ribosome repositioning in the human c-myc 5′UTR
    Carter, PS
    Jarquin-Pardo, M
    De Benedetti, A
    [J]. ONCOGENE, 1999, 18 (30) : 4326 - 4335
  • [16] Cher ML, 1996, CANCER RES, V56, P3091
  • [17] Cell type-dependent and -independent control of HER-2/neu translation
    Child, SJ
    Miller, MK
    Geballe, AP
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1999, 31 (01) : 201 - 213
  • [18] Crew JP, 2000, BRIT J CANCER, V82, P161
  • [19] DIFFERENTIAL EFFICIENCIES OF INVITRO TRANSLATION OF MOUSE C-MYC TRANSCRIPTS DIFFERING IN THE 5' UNTRANSLATED REGION
    DARVEAU, A
    PELLETIER, J
    SONENBERG, N
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (08) : 2315 - 2319
  • [20] De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347